Navigation Links
Takeda and Zinfandel Pharmaceuticals Sign Licensing Agreement for Alzheimer's Disease Biomarker in Combination with Pioglitazone
Date:1/10/2011

OSAKA, Japan and DURHAM, N.C., Jan. 10, 2011 /PRNewswire/ -- Takeda Pharmaceutical Company Limited and Zinfandel Pharmaceuticals, Inc. today announced that they have entered into an exclusive, worldwide licensing agreement regarding Zinfandel's TOMM40 assay as a biomarker for the risk of Alzheimer's disease in high-risk older adults with normal cognition. The companies will study pioglitazone in connection with the TOMM40 biomarker and Alzheimer's disease. Pioglitazone is the active ingredient currently marketed in Takeda's ACTOS® (pioglitazone HCl).

The TOMM40 biomarker, recently discovered by a team led by Allen Roses, M.D., Chief Executive Officer of Zinfandel, is being developed to identify individuals at high risk of developing Alzheimer's disease within the subsequent five years. Under this license agreement, Takeda and Zinfandel will attempt to prospectively validate the TOMM40 biomarker as a test of individual risk.

"There is intense interest within the medical community in identifying treatments to help delay progression or potentially prevent the onset of Alzheimer's disease, in an effort to reduce the burden of this disease," said Shigenori Ohkawa, Ph.D., Chief Scientific Officer, Takeda Pharmaceutical Company Limited. "We are energized by this partnership and the opportunity to develop an effective treatment for healthy at-risk older adults."

Under the terms of agreement, Zinfandel will receive an upfront payment of $9 million and subsequent payments of up to $78 million for development milestones from Takeda. Additional commercial milestones and royalties were also outlined in the agreement. Takeda will obtain an exclusive license, with the right to sublicense, develop, make, use and commercialize the TOMM40 biomarker assay, and to use the assay to identify high-risk older adults who would be candidates for clinical trials with pioglitazone to evaluate its utility.

"At Zinfandel, we have been exploring pharmacogene
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited; Zinfandel Pharmaceutcals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Takeda San Francisco, Inc. Appoints Gregory Landes, Ph.D. Vice President of Antibody Research
2. FDA Continues Review of Takedas New Drug Application for Alogliptin (SYR-322), a DPP-4 Agent for Type 2 Diabetes
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
4. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
5. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
6. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
7. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
8. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
9. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
10. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
11. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 2014 Stronger investment from private ... and consumer electronics will help fuel new growth ... firm IBISWorld has added a report on the ... report collection. , The Biometrics Scan Software industry ... such as fingerprint, iris, retina and face recognition ...
(Date:10/30/2014)... LONDON , October 30, 2014 ... Organovo Holdings Inc. (NYSE MKT: ONVO), Medivation Inc. (NASDAQ: ... PCYC ), Synthetic Biologics Inc. (NYSE MKT: SYN), and ... five companies can be accessed at: http://investor-edge.com/register ... Composite ended at 4,549.23, down 0.33%, the Dow Jones ...
(Date:10/30/2014)... Chicago, Illinois (PRWEB) October 30, 2014 ... Regenerative and Cellular Medicine Showcase in Chicago, leading ... and Orthopedic Surgeon, Dr. Wade McKenna presented talks ... Effectiveness and Orthopedic Surgical Applications For Stem Cells. ... of amniotic membrane and the properties of AlphaGEMS ...
(Date:10/30/2014)... Ontario (PRWEB) October 30, 2014 Spartan ... Spartan RX CYP2C19 System . It detects CYP2C19 ... non-invasive cheek swab. , The Spartan RX CYP2C19 System ... that has been approved in Canada. Due to the ... it may be used by healthcare professionals such as ...
Breaking Biology Technology:Biometrics Scan Software in the US Industry Market Research Report Now Available from IBISWorld 2Biometrics Scan Software in the US Industry Market Research Report Now Available from IBISWorld 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 4Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3
... A. How is fold amplification , ... using the Van Gelder and Eberwine technique (Van Gelder 1990) , ... polymerase , promoter for synthesis of ... at the end of mRNA sequences serves as the substrate for the , ...
... More thermostable than AMV RT and M-MLV RT , ... , Highly sensitive enzyme for ... for reverse transcribing transcripts with high , ... reverse transcriptase (RT) and , AMV RT, Ambion's HIV ...
... , Convenient format - premixed cap analog , ... RNA , 80% capping efficiency , ... , Ideal for microinjection, in vitro , ... The mMESSAGE mMACHINE High Yield , ...
Cached Biology Technology:RNA Amplification for Array Analysis 2RNA Amplification for Array Analysis 3RNA Amplification for Array Analysis 4Recombinant HIV Reverse Transcriptase 2Rapidly Synthesize Large Amounts of Capped RNA 2Rapidly Synthesize Large Amounts of Capped RNA 3Rapidly Synthesize Large Amounts of Capped RNA 4
(Date:10/29/2014)... bodies decompose, their types and numbers of bugs ... could mean the difference between a closed case ... is using a more than $866,000 U.S. Department ... examine these changing populations. The microbial communities may ... death, gender, race, socioeconomic relations and more, said ...
(Date:10/29/2014)... An innovative workflow reveals new research potential of the ... recently published article in the Biodiversity Data ... BOLD in tabular format and imported these into a ... Writting Tool (PWT). Data were used to study ... wasps from the Microgastrinae subfamily. , BOLD is originally ...
(Date:10/29/2014)... is a hormone released by the stomach and it ... as a psychoactive substance that primarily affects brain function, ... , This knowledge, combined with findings from animal studies, ... potential to stimulate alcohol craving. , Dr. Lorenzo Leggio ... that, as they had anticipated, alcohol craving was increased ...
Breaking Biology News(10 mins):MSU partners with Detroit to investigate death scenes 2Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2Ghrelin stimulates an appetite for drinking alcohol 2
... A Wayne State University physician is seeking a better ... disease (CMT), or inherited sensory-motor neuropathy, a disease that ... M.D., assistant professor of neurology in WSU,s School of ... CMT may be because researchers are measuring the wrong ...
... CO- It,s about living in two worlds times two, ... the University of Nebraska Medical Center in Omaha. Caplan ... Sir," about the divisions that science and national identity ... the Anaphora Literary Press of Cochran Georgia, "Welcome Home, ...
... -- MicroRNAs (miRNAs) that regulate processes including fertilization, development, ... They can be collected from routinely collected fluids such ... of factors can interfere with the accuracy of miRNA ... the Journal of Molecular Diagnostics , a group ...
Cached Biology News:Better CMT outcome measurement is Wayne State University physician's goal 2Better CMT outcome measurement is Wayne State University physician's goal 3New protocols improve detection of microRNAs for diagnosis 2New protocols improve detection of microRNAs for diagnosis 3